Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting PTP4A3 with KVX-053 mitigates alcohol-amplified SARS-CoV-2 spike protein-induced acute lung injury.

Frontiers in pharmacology·2026
Same author

The PTP4A3 inhibitor KVX-053 reduces Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virulence, inflammation, and development of acute lung injury in K18-hACE2 mice.

Respiratory research·2025
Same author

KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1-induced acute lung injury in mice.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Deletion of PTP4A3 phosphatase in high-grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release.

The Journal of pharmacology and experimental therapeutics·2025
Same author

KVX-053, a Protein Tyrosine Phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1 - induced acute lung injury in mice.

The Journal of pharmacology and experimental therapeutics·2024
Same author

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.

Nature medicine·2024
Same journal

Nanotechnology-Empowered Photodynamic Therapy for Improved Oral Cancer Treatment.

Anti-cancer agents in medicinal chemistry·2026
Same journal

Design, Synthesis, Spectroscopic Analysis, and In Silico Molecular Docking Study of Novel Azo Compounds as Potential Antioxidant and Anti-Triple-Negative Breast Cancer Agents.

Anti-cancer agents in medicinal chemistry·2026
Same journal

Plant-Derived Polyphenols in the Fight against Colorectal Cancer.

Anti-cancer agents in medicinal chemistry·2026
Same journal

Emerging Frontiers in Nanomedicine for Colorectal Cancer: A Review of Therapeutic Advances, Clinical Evidence, and Patented Technologies.

Anti-cancer agents in medicinal chemistry·2026
Same journal

Microfluidic Synthesis of miR-10a Antisense Oligonucleotides-Loaded LNP Combined with Cisplatin for Colorectal Cancer Therapy.

Anti-cancer agents in medicinal chemistry·2026
Same journal

Synergistic Anticancer Effect of Luteolin and Etoposide via the PI3K/AKT Signaling Pathway.

Anti-cancer agents in medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

Is Cdc25 a druggable target?

John S Lazo1, Peter Wipf

  • 1Department of Pharmacology and Chemical Biology, Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA. lazo@pitt.edu

Anti-Cancer Agents in Medicinal Chemistry
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Developing small molecule inhibitors for Cdc25 phosphatases is crucial for targeting cancer and Alzheimer's disease. This review summarizes strategies and challenges in creating these important therapeutic agents.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Experiment Videos

Last Updated: Jun 27, 2026

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • The Cdc25 phosphatase family plays a critical role in regulating cell cycle progression.
  • Dysregulation of Cdc25 phosphatases is linked to the development of cancer and Alzheimer's disease.
  • Cdc25 phosphatases are attractive targets for small molecule therapeutic interventions.

Purpose of the Study:

  • To review the rationale behind targeting Cdc25 phosphatases.
  • To discuss various approaches and progress in developing small molecule inhibitors for Cdc25.
  • To highlight the challenges and future directions in this field.

Main Methods:

  • Literature review of existing research on Cdc25 inhibitors.
  • Analysis of chemical probes and their characteristics.
  • Summary of strategies for inhibitor development.

Main Results:

  • Identification of Cdc25 phosphatases as key targets for cancer and Alzheimer's therapies.
  • Overview of diverse chemical scaffolds and strategies for Cdc25 inhibition.
  • Discussion of potential chemical probes and their properties.

Conclusions:

  • Small molecule inhibitors of Cdc25 phosphatases hold significant therapeutic potential.
  • Further research is needed to overcome challenges in developing effective and selective Cdc25 inhibitors.
  • Continued exploration of chemical probes will aid in advancing drug discovery for related diseases.